Last edition
News about "AstraZeneca"
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
AstraZeneca | 04/02/2026 | By News Bureau
AstraZeneca Boosts Weight Management Portfolio via CSPC Collaboration
Under this agreement, Astrazeneca and CSPC Pharmaceuticals will initially progress four programmes, which utilise CSPC's advanced Artificial Intelligence (AI)-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.
AstraZeneca | 31/01/2026 | By News Bureau
AstraZeneca Commits USD 15 Billion to Expand Manufacturing and R&D in China
UK-based pharmaceutical major AstraZeneca has announced a USD 15 billion investment in China by 2030, marking its largest-ever commitment to the country. The investment is aimed at expanding the company’s research, development and manufacturing capabilities, reinforcing China’s role as a key pillar in AstraZeneca’s global growth strategy.
AstraZeneca | 30/01/2026 | By Darshana
AstraZeneca Acquires Full Global Rights to AbelZeta's CAR-T Therapy C-CAR031 in USD 630 Million Deal
AstraZeneca has acquired AbelZeta Pharma’s China rights to CAR-T therapy C-CAR031 for up to USD 630 million, securing full global development and commercialisation rights for the liver cancer treatment.
AstraZeneca | 20/01/2026 | By News Bureau
EU Validates ENHERTU Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer
The European Union (EU) has validated the first-line use of ENHERTU in combination with pertuzumab for patients with HER2-positive metastatic breast cancer, following results from the DESTINY-Breast09 phase-III trial, which demonstrated a significant improvement in Progression-Free Survival (PFS) compared to current standard treatments.
AstraZeneca | 20/01/2026 | By News Bureau | 128
First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC
The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.
AstraZeneca | 14/01/2026 | By News Bureau | 107
Enhertu Secures US BTD Status in Early HER2-Positive Breast Cancer
The US FDA has granted Breakthrough Therapy Designation to Enhertu for use as post-neoadjuvant treatment in patients with HER2-positive early breast cancer, marking the tenth such designation for AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate, supported by phase III DESTINY-Breast05 trial results.
AstraZeneca | 23/12/2025 | By News Bureau
Jacobio Pharma Signs Global Licensing Deal with AstraZeneca for Pan-KRAS Drug
Under the agreement, Jacobio will receive USD 100 million upfront and is eligible for up to USD 1.915 billion in development and commercial milestones, along with tiered royalties on ex-China sales, while AstraZeneca will lead all ex-China development, regulatory and commercial activities for JAB-23E73.
AstraZeneca | 22/12/2025 | By News Bureau
AstraZeneca Secures CDSCO Approval for Breast Cancer Drug in India
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell and distribute its breast cancer therapy Datopotamab Deruxtecan in India.
AstraZeneca | 20/12/2025 | By Darshana | 114
EU Approves AstraZeneca's Saphnelo for Subcutaneous Self-Administration in Lupus
AstraZeneca has received approval from the European Commission for subcutaneous self-administration of Saphnelo (anifrolumab) using a pre-filled pen for adult patients with systemic lupus erythematosus, in addition to standard therapy.
AstraZeneca | 17/12/2025 | By Darshana | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy